Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2011 Nov 22;5 Suppl 8(Suppl 8):O2.
doi: 10.1186/1753-6561-5-S8-O2. eCollection 2011.

Recombinant antibody mixtures; optimization of cell line generation and single-batch manufacturing processes

Søren K Rasmussen  1 , Lars S Nielsen  1 , Christian Müller  1 , Thomas Bouquin  1 , Henrik Næsted  1 , Nina T Mønster  1 , Frank Nygaard  1 , Dietmar Weilguny  1 , Torben P Frandsen  1 , Anne B Tolstrup  1
Affiliations

Recombinant antibody mixtures; optimization of cell line generation and single-batch manufacturing processes

Søren K Rasmussen et al. BMC Proc. .
No abstract available

PubMed Disclaimer

Figures

Figure 1
Figure 1
A: Relative antibody ratios in pMCBs generated by mixing two ECHO cell lines at five different ratios. The antibody ratios were determined once a week by CIEX (from week 1 to 6 of cultivation) and in the harvest of a 14-day fed batch cultivation initiated after 6 weeks of cultivation. Red lines represent antibody 1 (Ab 1) and blue lines represent antibody 2 (Ab 2). B: Expected percentages plotted against measured percentages of Ab 1 in the five different mixes after 6 weeks seed train. C: Antibody compositions in pWCB in fed batch shaker experiments after 14, 21 and 28 days seed train, respectively. D:Antibody distributions in harvest from seven different 5 L bioreactor processes. Four pWCB-1 ampoules (blue columns) and three pWCB-2 ampoules (green columns) were used for seed train. The lighter colored columns represent mean ± sdev.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

References

    1. Ben-Kasus T, Schechter B, Lavi S, Yarden Y, Sela M. Persistent elimination of ErbB-2/HER2-overexpressing tumors using combinations of monoclonal antibodies: Relevance of receptor endocytosis. Proc Natl Acad Sci U S A. 2009;106:3294–3299. doi: 10.1073/pnas.0812059106. - DOI - PMC - PubMed
    1. van der Horst EH, Chinn L, Wang M, Velilla T, Tran H, Madrona Y, Lam A, Ji M, Hoey TC, Sato AK. Discovery of fully human anti-MET monoclonal antibodies with antitumor activity against colon cancer tumor models in vivo. Neoplasia. 2009;11:355–364. - PMC - PubMed
    1. Dong J, Demarest SJ, Sereno A, Tamraz S, Langley E, Doern A, Snipas T, Perron K, Joseph I, Glaser SM, Ho SN, Reff ME, Hariharan K. Combination of two insulin-like growth factor-I receptor inhibitory antibodies targeting distinct epitopes leads to an enhanced antitumor response. Mol Cancer Ther. 2010;9:2593–2604. doi: 10.1158/1535-7163.MCT-09-1018. - DOI - PubMed
    1. Fuentes G, Scaltriti M, Baselga J, Verma CS. Synergy between trastuzumab and pertuzumab for human epidermal growth factor 2 (Her2) from colocalization: an in silico based mechanism. Breast Cancer Res. 2011. in press . - PMC - PubMed
    1. Pedersen MW, Jacobsen HJ, Koefoed K, Hey A, Pyke C, Haurum JS, Kragh M. Sym004: Novel synergistic anti-epidermal growth factor receptor antibody mixture with superior anticancer efficacy. Cancer Res. 2010;15:588–597. - PubMed

LinkOut - more resources